Takeda Pharmaceutical Company Limited TAK
Set alert
As of Nov 2, 10:06 AM ET
- YTD
- +33.93%
- 1 year
- +55.36%
- Open
- 20.88
- Prev close
- 20.91
- Mkt cap
- 66.89B
- Vol
- 255.85K
- Avg vol
- 2.73M
- EPS
- 0.07
- P/E
- 299.07
- Div yield
- 2.41%
More statistics
- Low
- 20.84
- High
- 21.17
- Forward P/E
- 39.48
- Beta
- 0.10
- Short ratio
- 1.21
- Inst. own
- 3.32%
- Dividend
- 0.62
- Ex-div date
- Mar 30, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 18.78
- 200-d avg
- 17.53
- 1y target
- 23.08
5D chart
Events in this range
- Oct 29, 2026Earnings: 0.3852; estimate 0.145; surprise 165.66%
Signals (74)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| RSI: Overbought | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 10:35 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 4 days ago |
| RSI: Oversold | Oct 29, 9:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 29, 9:35 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 4 days ago |
| RSI: Oversold | Oct 28, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:15 PM | 4 days ago |
| RSI: Oversold | Oct 28, 2:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 6 days ago |
| MACD: Buy Signal | Oct 27, 10:25 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 6 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 6 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 1 week ago |
News
3 days ago seekingalpha.com
Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow
Takeda Pharmaceutical is reiterated as a Hold, with concerns about its ability to replace major drug revenues and current valuation. Operating margin improved to 17% due to lower amortization, but…
3 days ago marketbeat.com
What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
Takeda Pharmaceutical NYSE: TAK reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline…
3 days ago benzinga.com
Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
Takeda Pharmaceutical Co Ltd (NYSE:TAK) on Thursday reported second-quarter adjusted earnings of 48 cents per share, beating the consensus of 31 cents.
3 days ago benzinga.com
Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
Takeda Pharmaceutical (TAK) beats Q2 estimates and lifts fiscal 2026 guidance as pipeline growth and cost cuts balance off-patent Vyvanse losses.
3 days ago seekingalpha.com
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
4 days ago benzinga.com
Takeda Pharmaceutical Co Q2 2026 Earnings Call Transcript
Takeda Pharmaceutical Co (NYSE:TAK) reported second-quarter financial results on Thursday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is…
-
4 days ago benzinga.com
Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
Takeda Pharmaceutical Co (NYSE:TAK) Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
-
4 days ago benzinga.com
Takeda Pharmaceutical Q2 Adj. EPS $0.48 Beats $0.31 Estimate, Sales $7.457B Beat $7.190B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.31 by 54.84 percent. This is a 20 percent increase over earnings of…
4 days ago businesswire.com
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of…
-
1 week ago benzinga.com
Takeda Announces Results From Its Phase 3 G-HOPE-001 Study Of Arcotatug Tavatecan In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma; Arcotatug Tavatecan Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival, Showing Significant Improvements
Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual…
2 weeks ago benzinga.com
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
-
2 weeks ago benzinga.com
Takeda Announces New Data From VERDICT Showing That Treating Adults With Intravenous ENTYVIO To Achieve Corticosteroid-Free Disease Clearance Resulted In Significantly Longer Time To First Ulcerative Colitis-Related Complication, Reducing UC Complication Risk By Nearly 70%
Takeda ((TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF…
2 weeks ago benzinga.com
Ascentage Pharma Stock Could More Than Double: Analyst
William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.
-
2 weeks ago benzinga.com
Reported Earlier, Takeda Launches ORZEYFUL In Japan And China As First-In-Class Orexin Agonist For Narcolepsy Type 1, With US Launch Set For Next Month After DEA Scheduling
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA)…
-
1 month ago benzinga.com
Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis
Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete…
-
1 month ago benzinga.com
Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis ("MF") and anemia on concurrent…
1 month ago benzinga.com
Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development
Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authority, filed to go public Monday.
1 month ago benzinga.com
Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call
Takeda Pharmaceutical Co (NYSE:TAK) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga…
-
1 month ago benzinga.com
Takeda's Zasocitinib Shows About 70% Of Patients Achieving Clear Or Almost Clear Skin At Week 16 In Phase 3 LATITUDE PsO Studies Of Nearly 3,000 Patients
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pillResults from nearly 3,000…
-
1 month ago benzinga.com
Takeda's Phase 3 Trial Of Oveporexton's Data Published In New England Journal Of Medicine To Treat Narcolepsy Type 1; Oveporexton Generally Well-Tolerated With Consistent Safety Profile
Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist,…
2 months ago benzinga.com
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit control.
-
2 months ago benzinga.com
Takeda’s ORZEYFUL Wins Japan Approval For Narcolepsy Type 1 After Phase 3 Studies Show Significant Improvements Across Evaluated Symptoms
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1)Landmark Phase 3 Studies Demonstrated…
2 months ago benzinga.com
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
2 months ago benzinga.com
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’
Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more human-relevant methods.
2 months ago benzinga.com
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval
Takeda secured FDA approval for ORZEYFUL, a first-in-class oral orexin treatment for adults with narcolepsy type 1.
-
2 months ago benzinga.com
Takeda's ORZEYFUL Wins FDA Approval As First Orexin Therapy For Narcolepsy Type 1; U.S. Launch Planned Following DEA Scheduling
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on PlaceboAs a…
-
3 months ago benzinga.com
Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial
ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of elritercept versus epoetin alfa for the treatment of anemia due to very low, low, or…
-
3 months ago benzinga.com
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950…
-
3 months ago benzinga.com
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B
Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.
-
3 months ago benzinga.com
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.39 by 23.08 percent. This is a 7.69 percent decrease over earnings of…
3 months ago benzinga.com
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
Takeda shares positive Phase 3 data for its oral psoriasis drug zasocitinib, showing high skin clearance ahead of its planned FDA filing.
-
3 months ago benzinga.com
Reported July 16: Takeda Announces New Data From Two Phase 3 Studies Of Zasocitinib In Adults With Plaque Psoriasis; Secondary Endpoint Data Indicate Consistent And High Rates Of Skin Clearance
New data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe…
3 months ago benzinga.com
World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships
The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings, driven by lucrative collaborations with multinationals image credit: Bamboo Works Key
-
3 months ago benzinga.com
Reported Sunday, Takeda To Invest Up To $30M In Indonesia Plasma Ecosystem As Part Of Landmark Healthcare Collaboration With Indonesian Government, Including National Plasma Donation Network Pilot
Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi-Phased InitiativeTakeda Will Initially Invest…
4 months ago benzinga.com
Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine
Takeda and Insilico Medicine launch a strategic AI drug discovery collaboration to identify next-generation therapies.
4 months ago benzinga.com
This $300 Million Biotech May Be Deeply Mispriced: Analyst
Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major catalyst in the PV market.
-
4 months ago benzinga.com
Takeda Canada Announces Topline Results For Phase 3, Randomized, Multicenter, Double-Blind Study Comparing Zasocitinib To Deucravacitinib In Adults With Plaque Psoriasis
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis studyMore than 35% of zasocitinib-treated…
4 months ago benzinga.com
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran's profile against rusfertide.
4 months ago benzinga.com
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med
Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3 study, showing higher skin clearance rates.
-
4 months ago benzinga.com
Takeda Says Zasocitinib (TAK-279) Demonstrated Statistical Superiority Over Deucravacitinib In Moderate-To-Severe Plaque Psoriasis Patients
Takeda ((TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective…
-
4 months ago benzinga.com
FDA Accepts Review Of Takeda's Supplemental Biologics License Application For intravenous ENTYVIO
If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's diseasePotential for ENTYVIO to…
5 months ago benzinga.com
Jury Hits Takeda With $885 Million Antitrust Verdict
Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.
5 months ago benzinga.com
Takeda's Next Wave Of Drugs Has Investors Watching Closely
Takeda eyes growth with FDA Priority Reviews for narcolepsy and PV drugs. Get the latest on TAK's late-stage pipeline and 2026 forecasts.
-
5 months ago benzinga.com
Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.21 by 33.33 percent. This is a 75 percent increase over earnings of…
-
6 months ago benzinga.com
Takeda Announces That The TAK-881-300 Phase 2/3 Clinical Trial In Patients With Primary Immunodeficiency Disease 1 Met Its Primary Endpoint,
TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the…
6 months ago benzinga.com
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression
FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding its use beyond depression in a large market.
6 months ago benzinga.com
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2 data readout by late 2026.
-
7 months ago benzinga.com
Reported Friday, Denali Therapeutics Regains Full Rights To DNL593 After Takeda Terminates Collaboration, Phase 1/2 FTD-GRN Trial Results Expected By End Of 2026
Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technologyResults from ongoing Phase 1/2 study in patients with…
7 months ago benzinga.com
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda
Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.